News
Real-World Evidence in Medicine Development Course
[vc_row][vc_column][vc_column_text] The interactive online course Real-World Evidence in Medicine Development starts again on April 16th. Visit their website for more information. (http://www.imi-getreal.eu/Course)[/vc_column_text][/vc_column][/vc_row]
WP4 OTCA03 on “Screening of fetal trisomies 21, 18 and 13 by non invasive prenatal testing” is now available
This is the assessment of the relative effectiveness of “Screening of fetal trisomies 21, 18 and 13 by non invasive prenatal testing”. The purpose of
Proposed Regulation on HTA in Europe
Recent publication of the proposed Regulation on HTA in Europe WP1 Lead Partner, in its function as the EUnetHTA Directorate, acknowledges the recent publication of
Call for Comments – ATMP guideline on safety and efficacy follow-up and risk management
The revised ATMP guideline on safety and efficacy follow-up and risk management has been released for a 3-month public consultation (deadline of 30th April). EMA
WP4 PTJA03 on “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)” is now available
This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small
Final assessment report on MammaPrint® – Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer
Final Assessment Report, External Comments/Answers and Project Plan for Other Technologies CA MammaPrint® This is the assessment of the relative effectiveness of MammaPrint® – Added
EUnetHTA Magazine – Winter 2017-2018
Interview with Menno Aarnout/AIM, Partner Profiles: Portugal, Impact: Croatia and Italy, A Patient’s Perspective: Dr. Cees Smit, EMA-EUnetHTA Finalise Joint Work Plan, 2017-2020 winter_2017_magazine_final
An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report
An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report Background Health technology assessment (HTA) is the systematic evaluation of properties, effects,
Process of information retrieval for systematic reviews and health technology assessments on clinical effectiveness
EUnetHTA methodological guideline The guidance document reflects the current international status of information retrieval science. Although focused on information retrieval in regard to the effectiveness
EMA and EUnetHTA finalise joint work plan for 2017-2020
Medicines regulator and network of Health Technology Assessment (HTA) bodies continue to strengthen their collaboration The European Medicines Agency (EMA) and the European Network for
